An announcement from Medigene ( (DE:MDG1) ) is now available.
Medigene AG has announced its intention to file for insolvency proceedings due to an assessment of overindebtedness and anticipated illiquidity by May 2025. This decision, supported by the company’s Executive and Supervisory Boards, reflects a conservative reevaluation of the company’s asset valuation amidst challenging economic conditions, potentially impacting its operations and stakeholders.
More about Medigene
Medigene AG operates in the biotechnology industry, focusing on the development of innovative immunotherapies for the treatment of cancer. The company is known for its work in T cell receptor (TCR) technology and has a market presence in Germany, with its shares listed on the Frankfurt Stock Exchange.
YTD Price Performance: -27.25%
Average Trading Volume: 885
Technical Sentiment Signal: Strong Buy
Current Market Cap: €9.83M
Learn more about MDG1 stock on TipRanks’ Stock Analysis page.